Cargando…

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

We measured immunosuppression at myeloma diagnosis and assessed the impact on survival in 5826 UK myeloma trial patients. Polyclonal immunoglobulin levels were below normal in 85% of patients and above normal in only 0.4% of cases for IgA, 0.2% for IgM and no cases for IgG. Immunoparesis had a great...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heaney, Jennifer L. J., Campbell, John P., Iqbal, Gulnaz, Cairns, David, Richter, Alex, Child, J. Anthony, Gregory, Walter, Jackson, Graham, Kaiser, Martin, Owen, Roger, Davies, Faith, Morgan, Gareth, Dunn, Janet, Drayson, Mark T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087716/ https://www.ncbi.nlm.nih.gov/pubmed/29925902 http://dx.doi.org/10.1038/s41375-018-0163-4

Ejemplares similares

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020)

Clinical Considerations for Immunoparesis in Multiple Myeloma
por: Chahin, Michael, et al.
Publicado: (2022)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma
por: Huang, Weimin, et al.
Publicado: (2021)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
por: Chicca, Ilaria J., et al.
Publicado: (2020)

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
por: Bowcock, Stella, et al.
Publicado: (2023)

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2011)

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
por: Jackson, Graham H., et al.
Publicado: (2021)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2010)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
por: Shah, V, et al.
Publicado: (2018)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
por: Boyle, Eileen M, et al.
Publicado: (2015)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
por: Ramasamy, Karthik, et al.
Publicado: (2022)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
por: Fonseca, Rafael, et al.
Publicado: (2023)

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
por: Drayson, Mark T, et al.
Publicado: (2019)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
por: Coulson, Amy Beth, et al.
Publicado: (2022)

Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity
por: Heaney, Jennifer L. J., et al.
Publicado: (2022)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS
por: Seval, Guldane Cengiz, et al.
Publicado: (2022)

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients
por: Skerget, Matevz, et al.
Publicado: (2023)

Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
por: Croft, James, et al.
Publicado: (2020)

How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma
por: Morris, Treen Carson Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uciuoiekki17er1ic31ps8ps8b